Prudential PLC lowered its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 6.1% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 3,089,815 shares of the biopharmaceutical company’s stock after selling 199,735 shares during the quarter. Prudential PLC owned approximately 0.24% of Gilead Sciences worth $193,268,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also added to or reduced their stakes in GILD. Athena Capital Advisors LLC bought a new position in shares of Gilead Sciences in the 4th quarter worth approximately $27,000. Advisors Preferred LLC bought a new position in shares of Gilead Sciences in the 4th quarter worth approximately $31,000. Legacy Financial Advisors Inc. raised its position in shares of Gilead Sciences by 361.3% in the 4th quarter. Legacy Financial Advisors Inc. now owns 489 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 383 shares in the last quarter. We Are One Seven LLC bought a new position in shares of Gilead Sciences in the 4th quarter worth approximately $37,000. Finally, Larson Financial Group LLC bought a new position in shares of Gilead Sciences in the 4th quarter worth approximately $38,000. Institutional investors and hedge funds own 79.13% of the company’s stock.
Several brokerages have recently issued reports on GILD. Oppenheimer set a $85.00 target price on Gilead Sciences and gave the stock a “buy” rating in a research report on Tuesday. Zacks Investment Research lowered Gilead Sciences from a “hold” rating to a “sell” rating in a research report on Wednesday, January 23rd. BidaskClub lowered Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Thursday, February 7th. ValuEngine raised Gilead Sciences from a “sell” rating to a “hold” rating in a research report on Saturday, December 1st. Finally, BMO Capital Markets initiated coverage on Gilead Sciences in a research report on Thursday, March 14th. They set an “outperform” rating and a $78.00 price objective for the company. Two analysts have rated the stock with a sell rating, nine have issued a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $82.29.
Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Monday, February 4th. The biopharmaceutical company reported $1.44 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.70 by ($0.26). The firm had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.52 billion. Gilead Sciences had a return on equity of 37.03% and a net margin of 24.65%. The business’s quarterly revenue was down 2.6% on a year-over-year basis. During the same quarter last year, the business earned $1.78 earnings per share. On average, equities research analysts expect that Gilead Sciences, Inc. will post 6.23 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Thursday, March 28th. Stockholders of record on Friday, March 15th will be paid a $0.63 dividend. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.57. This represents a $2.52 dividend on an annualized basis and a dividend yield of 3.88%. The ex-dividend date of this dividend is Thursday, March 14th. Gilead Sciences’s dividend payout ratio (DPR) is 40.98%.
In other news, Director John Francis Cogan sold 2,700 shares of the firm’s stock in a transaction on Wednesday, March 20th. The stock was sold at an average price of $65.07, for a total value of $175,689.00. Following the transaction, the director now directly owns 57,560 shares in the company, valued at approximately $3,745,429.20. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Gayle E. Wilson sold 19,068 shares of the firm’s stock in a transaction on Tuesday, February 19th. The stock was sold at an average price of $67.08, for a total value of $1,279,081.44. Following the completion of the transaction, the director now owns 143,567 shares in the company, valued at $9,630,474.36. The disclosure for this sale can be found here. Company insiders own 1.16% of the company’s stock.
About Gilead Sciences
Gilead Sciences, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. Its primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.
Recommended Story: Derivative
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.